Skip to main content
 

Henry Masur, M.D.

Senior Investigator

Critical Care Medicine Department

NIH Clinical Center

Building 10, Room 2C145
10 Center Drive
Bethesda, MD 20892

301-496-9320

hmasur@cc.nih.gov

Research Topics

Dr. Masur was recruited to NIH to jointly found a new department of critical care medicine, and an HIV/AIDS program with NIAID. He became Chief of the Critical Care Medicine Department in 1989. During the past 20 years the department has attained national and international acclaim for its leadership in areas of sepsis, emerging infections, HIV/AIDS, lung biology, and sickle cell disease, and has developed a highly competitive, highly sought training program in critical care medicine which permits candidates to train in pulmonary medicine, infectious diseases, or cardiology as a second subspecialty. The department also has expanded its clinical services and serves as a pivotal component of the NIH Clinical Center which cares for patients with complex medical disorders. Dr. Masur is well known for his expertise in HIV-related opportunistic infections. His department has published many pivotal studies related in particular to pneumocystis pneumonia. He is the co-editor of the NIH-CDC-IDSA Guidelines for Management of Opportunistic Infections in Adults and Adolescents with HIV Infections, co-editor of the textbook AIDS Therapy, and past president of the Infectious Diseases Society of America. He is also well known in the field of critical care related to infectious diseases, and is the co-chair of IDSA-SCCM Guidelines on Prevention of Intravenous Catheter infections and Evaluation of Fever in the ICU. Dr. Masur leads the District of Columbia Partnership for AIDS Progress, a unique collaboration between NIH and the DC government that aims to create an urban model for decreasing the impact of HIV/AIDS on underserved populations. The program is focusing on HCV-HIV co-infection, mental health issues, and improving access and adherence to appropriate therapies. He is also active in the NIAID Project Phidisa, which works in South Africa with the National Defense Force to study HIV related therapies.

Biography

Dr. Masur earned his undergraduate degree from Dartmouth College and his medical degree from Cornell University Medical College. He completed his internship and residency in internal medicine at New York Hospital and Johns Hopkins Hospital. Following a fellowship at Cornell in the Division of Infectious Diseases and Internal Medicine, he served as an Instructor and assistant professor of medicine in the Infectious Diseases Division at Cornell from 1978 to 1982. He is Clinical Professor of Medicine at George Washington University and holds appointments at the University of Maryland and the Washington Hospital Center as well.

Selected Publications

  1. Castel AD, Kalmin MM, Hart RL, Young HA, Hays H, Benator D, Kumar P, Elion R, Parenti D, Ruiz ME, Wood A, D'Angelo L, Rakhmanina N, Rana S, Bryant M, Hebou A, Fernández R, Abbott S, Peterson J, Wood K, Subramanian T, Binkley J, Happ LP, Kharfen M, Masur H, Greenberg AE. Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC. AIDS Care. 2016;28(11):1355-64.
  2. Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Shrivastava S, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, Kottilil S. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clin Infect Dis. 2016;62(4):440-7.
  3. Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A, Kottilil S. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clin Infect Dis. 2016;62(3):280-8.
  4. Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015;385(9973):1107-13.
  5. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232-9.
This page was last updated on May 1st, 2013